Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate

Nathan, Robert A.; Nayak, Anjuli; Graft, David F.; Lawrence, Michael C.; Picone, Frank J.; Ahmed, Tahir; Wolfe, James; Vanderwalker, Mark L.; Nolop, K. B.; Je, Harrison

doi:10.1016/s1081-1206(10)62692-0

Cited by 51 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(35) and BDP 168 μg b.i.d. (30) in improving FEV 1 . In addition, one study found that MF-DPI 440 μg (metered dose) q.d.…”

Section: Comparative Efficacymentioning

confidence: 93%

“…Seven clinical studies (29)(30)(31)(32)(33)(34)(35) have evaluated MF-DPI in patients with mild to moderate asthma previously taking ICS. In 3 of these studies (30,34,35), other ICS served as active controls (see Comparative Efficacy section).…”

Section: Patients With Mild To Moderate Asthma Previously Using Icsmentioning

confidence: 99%

“…In 3 of these studies (30,34,35), other ICS served as active controls (see Comparative Efficacy section). An early placebo-controlled dose-ranging study in 365 patients evaluated twice-daily administration of MF-DPI (100 μg, 200 μg, or 400 μg) and twice-daily administration of beclomethasone Two additional, placebo-controlled studies have been conducted to evaluate the efficacy of q.d.…”

Section: Patients With Mild To Moderate Asthma Previously Using Icsmentioning

confidence: 99%

See 2 more Smart Citations

The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

Meltzer

Wenzel

2006

Journal of Asthma

View full text Add to dashboard Cite

Inhaled corticosteroids are the gold standard of daily therapy for effective control of all stages of persistent asthma. For this review of the new inhaled corticosteroid mometasone furoate, a MEDLINE/PubMed search using the terms "mometasone furoate AND asthma" found 57 articles, 17 of which presented data from efficacy and safety studies reviewed herein. In clinical trials, once-daily evening dosing of mometasone furoate delivered via dry powder inhaler (200 or 400 mu g/day) was effective in patients with mild to moderate asthma previously treated with short-acting beta2-agonists alone and in those previously maintained on inhaled corticosteroid therapy. In patients with severe asthma, mometasone furoate 400 mu g twice daily eliminated or reduced the need for oral prednisone while improving lung function, asthma symptoms, and quality of life. Clinical studies have shown that mometasone furoate is generally well tolerated and has minimal systemic activity at recommended doses. In conclusion, mometasone furoate provides primary care and specialty physicians with a safe, effective, and convenient option to meet the challenges of asthma management.

show abstract

“…(35) and BDP 168 μg b.i.d. (30) in improving FEV 1 . In addition, one study found that MF-DPI 440 μg (metered dose) q.d.…”

Section: Comparative Efficacymentioning

confidence: 93%

Section: Patients With Mild To Moderate Asthma Previously Using Icsmentioning

confidence: 99%

Section: Patients With Mild To Moderate Asthma Previously Using Icsmentioning

confidence: 99%

See 1 more Smart Citation

The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

Meltzer

Wenzel

2006

Journal of Asthma

View full text Add to dashboard Cite

show abstract

“…Studies have consistently shown that FP and budesonide have less systemic effects than BDP, triamcinolone and flunisolide [33]. The newer ICS mometasone and ciclesonide are claimed to have less systemic effects [69,70]. …”

Section: Clinical Usementioning

confidence: 99%

Inhaled Corticosteroids

2010

View full text Add to dashboard Cite

Inhaled corticosteroids (ICS) are the most effective controllers of asthma. They suppress inflammation mainly by switching off multiple activated inflammatory genes through reversing histone acetylation via the recruitment of histone deacetylase 2 (HDAC2). Through suppression of airway inflammation ICS reduce airway hyperresponsiveness and control asthma symptoms. ICS are now first-line therapy for all patients with persistent asthma, controlling asthma symptoms and preventing exacerbations. Inhaled long-acting β2-agonists added to ICS further improve asthma control and are commonly given as combination inhalers, which improve compliance and control asthma at lower doses of corticosteroids. By contrast, ICS provide much less clinical benefit in COPD and the inflammation is resistant to the action of corticosteroids. This appears to be due to a reduction in HDAC2 activity and expression as a result of oxidative stress. ICS are added to bronchodilators in patients with severe COPD to reduce exacerbations. ICS, which are absorbed from the lungs into the systemic circulation, have negligible systemic side effects at the doses most patients require, although the high doses used in COPD has some systemic side effects and increases the risk of developing pneumonia.

show abstract

“…Other new ICS formulations are being considered that increase lung tissue binding to lower the drug delivered to the systematic circulation. [54]. Alternative strategies to lower the C o p y r ig h t G e n e r a l P r a c t ic e A ir w a y s G r o u p R e p r o d u c t io n p r o h ib it e d total daily dose of ICS include the addition of longacting bronchodilators or leukotriene modifiers in people with moderate to severe asthma, but not in those patients with mild persistent asthma [55][56][57][58].…”

Section: Systemic Corticosteroidsmentioning

confidence: 99%

Asthma management: Are GINA guidelines appropriate for daily clinical practice?

Yawn

Molen

Humbert

2005

Primary Care Respiratory Journal

View full text Add to dashboard Cite

SummaryAn international group of primary care asthma experts, as well as pulmonologists and allergists from Europe and the US, met to discuss asthma management focused on the primary care office. This paper summarizes their discussions. Accuracy of diagnosis and appropriateness of treatment is variable depending on the clinical circumstances and patient group. The value of classifying patients based on baseline or static asthma severity scores remains controversial, and asthma management decisions based on symptom control appear to have greater practical utility in a primary care setting. Furthermore, it must be recognized that patients, caregivers and physicians may have differing, and possibly conflicting, goals for therapy. There are many initiatives to improve the quality of asthma management, for example, primary care-focused guidelines being developed by the International Primary Care Respiratory Group, and several groups are working on asthma control scores. In addition, new therapies may improve the options available for increasing compliance and reducing side effects. In conclusion, asthma management should be patient-focused, with outcomes relevant to improving the quality of life for people with asthma.

show abstract

Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate

Cited by 51 publications

References 18 publications

The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

The Efficacy and Safety of Mometasone Furoate Delivered via a Dry Powder Inhaler for the Treatment of Asthma

Inhaled Corticosteroids

Asthma management: Are GINA guidelines appropriate for daily clinical practice?

Contact Info

Product

Resources

About